Valneva SE (VALN) EBITDA Margin (2021 - 2026)
Valneva SE's (VALN) quarterly EBITDA Margin came in at 59.64% in Q1 2026, down 5840.0% year-on-year from 1.04% in Q1 2025, and down 5.81% quarter-over-quarter from 56.36% in Q4 2025.
Valneva SE (VALN) EBITDA Margin (2021 - 2026) Analysis & Trends
Valneva SE has disclosed EBITDA Margin across 6 years of filings, most recently posting 59.64% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 59.64%, down 5840.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 55.48% (down 3275.0% YoY), and the FY2025 annual result was 37.62%, down 5777.0% from the prior year.
- EBITDA Margin came in at 59.64% for Q1 2026 at Valneva SE, down from 56.36% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 93862.2% in Q4 2022 to a low of 92077.59% in Q3 2022.
- The 5-year median for EBITDA Margin is 42.58% (2023), against an average of 41.59%.
- Across the five-year window, EBITDA Margin soared 9285613 bps in 2022 and plunged 9390255 bps in 2023, its largest moves.
- Valneva SE's EBITDA Margin stood at 93862.2% in 2022, then plunged by 100 bps to 40.35% in 2023, then gained by 23 bps to 30.91% in 2024, then sank by 82 bps to 56.36% in 2025, then dropped by 6 bps to 59.64% in 2026.
- The last three EBITDA Margin figures came in at 59.64% (Q1 2026), 56.36% (Q4 2025), and 111.7% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -59.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -59.64% |
| Dec 31, 2025 | -56.36% |
| Sep 30, 2025 | -111.70% |
| Jun 30, 2025 | -12.73% |
| Mar 31, 2025 | -1.23% |
| Dec 31, 2024 | -30.91% |
| Sep 30, 2024 | -17.19% |
| Jun 30, 2024 | -46.50% |
| Mar 31, 2024 | 227.07% |
| Dec 31, 2023 | -40.35% |
| Sep 30, 2023 | -48.55% |
| Jun 30, 2023 | -42.58% |
| Mar 31, 2023 | -38.32% |
| Dec 31, 2022 | 93,862.20% |
| Sep 30, 2022 | -92,077.59% |
| Jun 30, 2022 | -684.80% |
| Mar 31, 2022 | -113.85% |
| Dec 31, 2021 | 1,006.07% |
| Sep 30, 2021 | -1,104.77% |
| Jun 30, 2021 | -331.24% |